Presentation to be held on Tuesday, November 7, 2023 from 4:45 –
5:00 p.m. UTC
AUSTIN,
Texas, Nov. 1, 2023 /PRNewswire/ -- Genprex, Inc.
("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene
therapy company focused on developing life-changing therapies for
patients with cancer and diabetes, today announced its Executive
Vice President, General Counsel and Chief Strategy Officer,
Catherine Vaczy, will be providing
an overview of the Company's gene therapies for cancer and diabetes
at the upcoming BIO-Europe 2023 Conference taking place in
Munich, Germany.
Event: BIO-Europe 2023 Conference
Conference Dates: Nov. 6 – 8, 2023
Presentation Date: Tuesday, Nov. 7, 2023
Presentation Time: 4:45 p.m UTC
Presenter: Catherine Vaczy, Genprex's Executive Vice
President, General Counsel and Chief Strategy Officer
In attendance at BIO-Europe 2023 will be several members of
Genprex's executive leadership team. For those interested in
meeting Genprex management during BIO-Europe 2023, please request a
meeting through the conference portal or reach out to investor
relations at investors@genprex.com.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage
gene therapy company focused on developing life-changing therapies
for patients with cancer and diabetes. Genprex's technologies are
designed to administer disease-fighting genes to provide new
therapies for large patient populations with cancer and diabetes
who currently have limited treatment options. Genprex works with
world-class institutions and collaborators to develop drug
candidates to further its pipeline of gene therapies in order to
provide novel treatment approaches. Genprex's oncology program
utilizes its systemic, non-viral ONCOPREX® Nanoparticle Delivery
System which encapsulates the gene-expressing plasmids using lipid
nanoparticles. The resultant product is administered intravenously,
where it is taken up by tumor cells that then express tumor
suppressor proteins that were deficient in the tumor. The Company's
lead product candidate, REQORSA® (quaratusugene ozeplasmid), is
being evaluated in three clinical trials as a treatment for
non-small cell lung cancer (NSCLC) and small cell lung cancer
(SCLC). Each of Genprex's three lung cancer clinical programs has
received a Fast Track Designation from the FDA for the treatment of
that patient population, and Genprex's SCLC program has received an
FDA Orphan Drug Designation. Genprex's diabetes gene therapy
approach is comprised of a novel infusion process that uses an
adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes
directly to the pancreas. In models of Type 1 diabetes, GPX-002
transforms alpha cells in the pancreas into functional beta-like
cells, which can produce insulin but may be distinct enough from
beta cells to evade the body's immune system. In a similar
approach, GPX-003 for Type 2 diabetes, where autoimmunity is not at
play, is believed to rejuvenate and replenish exhausted beta
cells.
Interested investors and shareholders are encouraged to sign up
for press releases and industry updates by visiting
the Company Website, registering for Email
Alerts and by following Genprex on Twitter, Facebook and
LinkedIn.
Cautionary Language Concerning Forward-Looking
Statements
Statements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are made on the basis of the current beliefs,
expectations and assumptions of management, are not guarantees of
performance and are subject to significant risks and uncertainty.
These forward-looking statements should, therefore, be considered
in light of various important factors, including those set forth
in Genprex's reports that it files from time to time
with the Securities and Exchange Commission and which you should
review, including those statements under "Item 1A – Risk Factors"
in Genprex's Annual Report on Form 10-K for the year
ended December 31, 2022.
Because forward-looking statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding:
Genprex's ability to advance the clinical development,
manufacturing and commercialization of its product candidates in
accordance with projected timelines and specifications; the timing
and success of Genprex's clinical trials and regulatory approvals;
the effect of Genprex's product candidates, alone and in
combination with other therapies, on cancer and diabetes; Genprex's
future growth and financial status, including Genprex's ability
to continue as a going concern and to obtain capital to meet
its long-term liquidity needs on acceptable terms, or at all;
Genprex's commercial and strategic partnerships, including those
with its third party vendors, suppliers and manufacturers and their
ability to successfully perform and scale up the manufacture of its
product candidates; and Genprex's intellectual property and
licenses.
These forward-looking statements should not be relied upon as
predictions of future events and Genprex cannot assure you that the
events or circumstances discussed or reflected in these statements
will be achieved or will occur. If such forward-looking statements
prove to be inaccurate, the inaccuracy may be material. You should
not regard these statements as a representation or warranty by
Genprex or any other person that Genprex will achieve its
objectives and plans in any specified timeframe, or at all. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Genprex disclaims any obligation to publicly update or release any
revisions to these forward-looking statements, whether as a result
of new information, future events or otherwise, after the date of
this press release or to reflect the occurrence of unanticipated
events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor
Relations
investors@genprex.com
GNPX Media Contact
Kalyn
Dabbs
media@genprex.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/genprex-to-present-at-bio-europe-2023-conference-301973792.html
SOURCE Genprex, Inc.